eligibility_summary
Adults ≥18 with ≥1 claim for OMB therapy (index = first OMB claim), ≥1 MS diagnosis claim (ICD-10 G35.xx) any time before to 6 months after index, continuous health plan enrollment ≥12 months pre- and ≥12 months post-index, and persistent OMB use during the post period (no discontinuation or switch). No exclusion criteria.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Ofatumumab (OMB), a fully human IgG1κ anti‑CD20 monoclonal antibody for relapsing MS, administered subcutaneously. Mechanism: binds a membrane‑proximal epitope on CD20 on B cells, inducing B‑cell depletion via complement‑dependent cytotoxicity and Fc‑mediated ADCC/ADCP, reduces pathogenic B‑cell antigen presentation and proinflammatory cytokine signaling, indirectly dampening T‑cell activation. Targets: CD20+ B lymphocytes (pre‑B, naïve, memory, spares stem cells and plasma cells) and downstream CNS inflammatory pathways. Study: retrospective real‑world pre/post cohort of MS patients initiating OMB (anti‑CD20‑naïve and experienced), outcomes included annualized relapse rate and MS‑related healthcare utilization.